Asmita Mukherjee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Asmita Mukherjee has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Archana Tripathi
Department of Biological Sciences, Indian Institute of Science Education and Research Kolkata, Mohanpur-741246, India
2 shared publications - Argha Mario Mallick
Department of Biological Sciences, Indian Institute of Science Education and Research Kolkata, Mohanpur-741246, India
2 shared publications - Rituparna Sinha Roy
Indian Institute of Science Education and Research Kolkata
2 shared publications - Abhijit Biswas
Department of Chemical Sciences, Indian Institute of Science Education and Research Kolkata, Mohanpur- 741246, West Bengal, India
1 shared publication - Ananya Chatterjee
Department of Biological Sciences, Indian Institute of Science Education and Research Kolkata, Mohanpur-741246, India
1 shared publication - Arnab Mukherjee
Indian Institute of Science Education and Research Pune
1 shared publication
Latest Publications
- 21 June 2024
- Published by Royal Society of Chemistry (RSC) in Biomaterials Science
- Vol. 12 (14) , 3582-3599
Nanostructured lipopeptide-based membranomimetics for stabilizing bacteriorhodopsin
Engineered lipopeptide-based facial detergents having a linear unstructured or cyclic (β-turn) conformation can stabilize the model integral membrane protein, bacteriorhodopsin.
- 21 June 2024
- Published by Royal Society of Chemistry (RSC) in Biomaterials Science
- Vol. 12 (14) , 3582-3599
Nanostructured lipopeptide-based membranomimetics for stabilizing bacteriorhodopsin
Engineered lipopeptide-based facial detergents having a linear unstructured or cyclic (β-turn) conformation can stabilize the model integral membrane protein, bacteriorhodopsin.
- 30 June 2022
- Published by Wiley in Chemistry – An Asian Journal
- Vol. 17 (16) , e202200451
Emerging Approaches for Enabling RNAi Therapeutics
RNA interference (RNAi) is a primitive evolutionary mechanism developed to escape incorporation of foreign genetic material. siRNA has been instrumental in achieving the therapeutic potential of RNAi by theoretically silencing any gene of interest in a reversible and sequence‐specific manner. Extrinsically administered siRNA generally needs a delivery vehicle to span across different physiological barriers and load into the RISC complex in the cytoplasm in its functional form to show its efficacy. This review discusses the designing principles and examples of different classes of delivery vehicles that have proved to be efficient in RNAi therapeutics. We also briefly discuss the role of RNAi therapeutics in genetic and rare diseases, epigenetic modifications, immunomodulation and combination modality to inch closer in creating a personalized therapy for metastatic cancer. At the end, we present, strategies and look into the opportunities to develop efficient delivery vehicles for RNAi which can be translated into clinics.
- 30 June 2022
- Published by Wiley in Chemistry – An Asian Journal
- Vol. 17 (16) , e202200451
Emerging Approaches for Enabling RNAi Therapeutics
RNA interference (RNAi) is a primitive evolutionary mechanism developed to escape incorporation of foreign genetic material. siRNA has been instrumental in achieving the therapeutic potential of RNAi by theoretically silencing any gene of interest in a reversible and sequence‐specific manner. Extrinsically administered siRNA generally needs a delivery vehicle to span across different physiological barriers and load into the RISC complex in the cytoplasm in its functional form to show its efficacy. This review discusses the designing principles and examples of different classes of delivery vehicles that have proved to be efficient in RNAi therapeutics. We also briefly discuss the role of RNAi therapeutics in genetic and rare diseases, epigenetic modifications, immunomodulation and combination modality to inch closer in creating a personalized therapy for metastatic cancer. At the end, we present, strategies and look into the opportunities to develop efficient delivery vehicles for RNAi which can be translated into clinics.